Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple rinse reveal ovarian Cancer's earliest signs?

NCT ID NCT07772869

Diagnosis Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Sep 09, 2026 · Updated 4 times

Summary

This study explores whether a uterine lavage—a procedure that rinses the fallopian tubes with saline to collect cells—can help detect early genetic changes linked to ovarian cancer in women with BRCA mutations. Participants are high-risk women planning risk-reduction surgery. Researchers will analyze the collected cells for TP53 mutations, which are often the first step in cancer development, to see if this approach could serve as a future screening tool.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Uterine lavage (a procedure that rinses the fallopian tubes with saline to collect cells for analysis)
What this could lead to
If successful, this could lead to a non-surgical screening method to detect early signs of ovarian cancer in high-risk women, potentially enabling earlier intervention.
What could go wrong
This is an early-stage study with a small number of participants. The procedure may not reliably detect cancer-related changes, and more research will be needed before it could be used as a screening test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \> 18 years of age * Have a pathogenic BRCA1 or BRCA2 germline variant * Planned risk-reduction surgery * Presence of uterus and at least one fallopian tube Exclusion Criteria: * Prior tubal ligation * Prior history of known ovarian or endometrial cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA hereditary ovarian carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube serous adenocarcinoma familial ovarian carcinoma ovarian serous adenocarcinoma primary peritoneal serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA hereditary ovarian carcinoma Fallopian tube high grade serous adenocarcinoma Ovarian high grade serous adenocarcinoma Primary peritoneal high grade serous adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.